Fig. 1: A hotspot splice-disrupting GATA3 mutation correlates with good outcome in breast cancer.
From: The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
a Distribution of the GATA3 mutations in the METABRIC, TCGA-BRCA, and MSK-IMPACT cohorts (only BC patients are shown for the latter). The two GATA boxes indicate the two Zn finger DNA-binding domains of the GATA3 protein. b Scheme of the mutant transcript identified in tumors carrying the X308_Splice mutation, compared with tumors with wt GATA3 or with any other GATA3 mutation. c Top: schematic representation of wt GATA3, compared with the predicted neoGATA3 protein. Bottom: western blot showing the expression of wild type GATA3 (wtG3) and the mutant neoGATA3. Black arrows indicate the proteins of the expected size. d Representative IHC images using either the N-ter GATA3 antibody—recognizing both wt and mutant GATA3 (left)—or the neoGATA3-specific antibody (right) on tumors carrying wild type GATA3 (top), or the X308_Splice mutation (bottom). e Kaplan–Meier survival curves of the METABRIC patients stratified according to GATA3 status (WT = wild type, neoGATA3 = all mutations producing a neoGATA3-like peptide, OtherMut = all other mutations in GATA3). Left: all patients, right: ER + patients.
